Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Solid Tumors 1Pleural Effusion 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Multiple Myeloma 1Insulin-Like Growth Factor I, Resistance To 1Advanced Solid Tumors 1

Interventions

Carboplatin 341Paclitaxel 262Cisplatin 233Pemetrexed 226Docetaxel 206Erlotinib Hydrochloride 193Gemcitabine 178pembrolizumab 137Bevacizumab 121Radiotherapy 118Nivolumab 84Gefitinib 73Vinorelbine 64Cetuximab 58atezolizumab 47Afatinib 46durvalumab 44osimertinib 41Radiosurgery 35Ipilimumab 34Drug Therapy 32Taxes 30Albumin-Bound Paclitaxel 29130-nm albumin-bound paclitaxel 29Surgical Procedures, Operative 28Etoposide 25Irinotecan 24Sorafenib 21Cyclophosphamide 20Radiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Carcinoma, Non-Small-Cell Lung × dalotuzumab × Clear all
NCT00654420 2018-08-08

A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

Merck Sharp & Dohme LLC

Phase 2 Completed
95 enrolled 13 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00729742 2016-04-04

Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Merck Sharp & Dohme LLC

Phase 1 Completed
49 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00799240 2014-11-07

IMPACT

University of Kansas Medical Center

Phase 2 Completed
27 enrolled
Thoracic

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡